Erlotinib (Tarceva): an update on the clinical trial program.

@article{Herbst2003ErlotinibA,
  title={Erlotinib (Tarceva): an update on the clinical trial program.},
  author={Roy S. Herbst},
  journal={Seminars in oncology},
  year={2003},
  volume={30 3 Suppl 7},
  pages={34-46}
}
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available, quinazoline-based agent that competes with adenosine triphosphate for binding with the intracellular catalytic domain of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase, inhibiting phosphorylation. This action blocks downstream signal transduction and inhibits the tumorigenic effects associated with ligand-dependent and ligand-independent HER1/EGFR activation. In preclinical studies, erlotinib… CONTINUE READING